Clinical-stage biopharmaceutical developer Definium Therapeutics announced positive topline results from two pivotal Phase 3 trials evaluating DT120 orally disintegrating tablets. The randomized, double-blind studies—designated Voyage and Panorama—met primary endpoints in adult patients diagnosed with Generalized Anxiety Disorder. Chief Medical Officer at Definium stated: "Topline findings across Voyage and Panorama substantiate the potential of DT120 ODT to provide rapid and durable clinical relief for patients with GAD."
DT120 ODT utilizes a proprietary pharmaceutically optimized tartrate salt formulation of lysergide engineered to dissolve rapidly without oral liquid co-administration. Treated participants demonstrated statistically significant reductions in Hamilton Anxiety Rating Scale scores compared to placebo groups. More than 50 million individuals in the United States live with Generalized Anxiety Disorder, where traditional medications frequently carry sedation side effects.
Safety profiles remained favorable throughout clinical monitoring, with adverse events predominantly limited to transient, same-day mild effects. The drug candidate previously secured Breakthrough Therapy Designation from the U.S. Food and Drug Administration to accelerate clinical development. Definium confirmed ongoing preparation of full chemistry, manufacturing, and control dossiers to support regulatory submissions.
The pharmaceutical company intends to file a formal New Drug Application with federal regulators during the first half of 2027.
